Clinical trials: Rare Malignant Neoplasm
Rare Cancers, Multiomics
Molecularly Aided Stratification for Tumor Eradication Research
NCT/DKFZ/DKTK MASTER is a prospective, continuously recruiting, multicenter observational study for biology-guided stratification of adults with rare cancers, including rare subtypes of common entities, using comprehensive…
- Trial name
- NCT-MASTER (NCT05852522)
- Where
- Germany
- Volunteers
- 10,000 people
- Sponsor
- German Cancer Research Center
Rare Tumor
PLATFORM Study of Precision Medicine for Rare Tumors
A Phase II, open label, non-randomized, multiple-arm, single-center clinical trial in patients with advanced rare solid tumors who failed to standard treatment.
- Trial name
- NCT04423185
- Testing
- Almonertinib 110 MG, Dacomitinib 45 MG, Alectinib 150 MG
- Where
- China
- Volunteers
- 770 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Cancer, Breast Cancer
Genomic Investigation of Unusual Responders
Studies have shown that tumors from the same patient may respond very differently to the same therapeutic agents. This study aims to investigate the genetic basis of tumors that respond abnormally well or poorly to therapeutic…
- Conditions
- Cancer, Breast Cancer, Non-small Cell Lung Cancer, Colorectal Cancer
- Trial name
- GENIUS (NCT03740503)
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- University Health Network, Toronto
Rare Tumour
Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS
The objective of this Phase II, open-label, multicenter, non-randomised controlled clinical trial is to guide precision treatment for patients with rare tumours based on Patient-Derived Organoids/Next-Generation Sequencing drug…
- Trial name
- SPRING (NCT06692491)
- Testing
- Albumin-Bound Paclitaxel, Epirubicin, Gemcitabine
- Volunteers
- 200 people
- Sponsor
- Peking University Shenzhen Hospital
Head Neck Tumors, Neuroendocrine Tumors
A Phase II Study on Adjuvant Vaccination with Dendritic Cells Loaded with Autologous Tumor Homogenate in Resected Stage IV Rare Cancers.
Single-arm, monocentric trial to assess safety and immunological efficacy of adjuvant vaccination with autologous dendritic cells loaded with autologous tumour homogenate after curative resection for stage IV rare cancers (In…
- Conditions
- Head Neck Tumors, Neuroendocrine Tumors, Soft Tissue Sarcoma, Rare Cancer
- Trial name
- RaC-Ad (NCT04166006)
- Testing
- Autologous DC vaccine, Interleukin-2
- Where
- Italy
- Volunteers
- 51 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Neuroblastoma, Medulloblastoma
Molecular-Guided Therapy for Relapsed and Refractory Childhood Cancer
The purpose of this study is to test the feasibility (ability to be done) of experimental technologies to determine a tumor's molecular makeup (gene expression profile) and mutations.
- Conditions
- Neuroblastoma, Medulloblastoma, Brain Tumors, Rare Tumors
- Trial name
- NCT01802567
- Testing
- Guided Therapy- Pediatric Gene Analysis Platform
- Where
- 13 sites in United States
- Volunteers
- 52 people
- Sponsor
- Giselle Sholler
Neuroblastoma, Nephroblastoma
Psychosocial Situation of Children With Rare Solid Abdominal Tumors and Their Families
Families of children with rare diseases (i.e., not more than 5 out of 10.000 people are affected) are often highly burdened with fears, insecurities and concerns regarding the affected child and his/her siblings.
- Conditions
- Neuroblastoma, Nephroblastoma, Hepatoblastoma
- Trial name
- PsyRareCare (NCT05245123)
- Where
- 2 sites in Germany
- Volunteers
- 100 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Rare Malignant Neoplasm
Marker Assisted Selective ThErapy in Rare Cancers: Knowledge Database Establishing registrY Asia
This is a registry study that aims to collect patients' data with advanced-stage rare cancer in Asia-Pacific region. Data includes clinical information, details of treatment, prognosis, pathological diagnosis and genetic…
- Trial name
- MASTERKEY ASIA (NCT05217407)
- Testing
- Genomic sequence
- Where
- 18 sites in Japan, Malaysia and 5 more
- Volunteers
- 1,000 people
- Sponsor
- National Cancer Center, Japan
Ewing's Sarcoma, Ewing Family of Tumors
Pbi-shRNA™ EWS/FLI1 Type 1 LPX in Subjects With Advanced Ewing's Sarcoma
The purpose of this study is to determine the safety and the maximum tolerated dose of of pbi-shRNA™ EWS/FLI1 Type 1 lipoplex in patients with advanced Ewing's sarcoma.
- Conditions
- Ewing's Sarcoma, Ewing Family of Tumors, Ewing's Tumor Metastatic, Ewing's Sarcoma Metastatic
- Trial name
- NCT02736565
- Testing
- pbi-shRNA™ EWS/FLI1 Type 1 Lipoplex
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- Gradalis, Inc.
Rare Gynecological Tumors, Multi-omics Analysis
Prospective Multi-omics Observational Study of Gynecological Rare Pathological Tumors
The goal of this observational study is to draw the characteristic maps of genomics, transcriptome, proteomics, metabolomics, etc. in 600 patients with gynecological rare pathological types of malignant tumors.
- Trial name
- NCT05985941
- Volunteers
- 600 people
- Sponsor
- RenJi Hospital
Endocrine Tumor
A Research Registry on Aggressive PitNETs
To allow the identification of markers, it is necessary to extend research networks more widely to collect and properly explore aggressive pituitary tumours.
- Trial name
- RECAPitNETT (NCT05974696)
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Hospices Civils de Lyon
HER2-positive Breast Cancer, HER2 Gene Mutation
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Open-label, Phase I-II, first-in-human (FIH) study for A166 monotherapy in HER2-expressing or amplified patients who progressed on or did not respond to available standard therapies.
- Conditions
- HER2-positive Breast Cancer, HER2 Gene Mutation, HER-2 Gene Amplification, HER2 Positive Gastric Cancer
- Trial name
- NCT03602079
- Testing
- A166
- Where
- 10 sites in United States
- Volunteers
- 49 people
- Sponsor
- Klus Pharma Inc.
Ewing Sarcoma, Ewing Family of Tumors
A Trial For Participants With Ewing's Sarcoma Treated With Vigil in Combination With Irinotecan and Temozolomide
The goal of this clinical trial was to compare participants with first relapse or refractory Ewing's sarcoma when treated with investigational product (Vigil) in addition to the standard treatment of irinotecan and temozolomide…
- Conditions
- Ewing Sarcoma, Ewing Family of Tumors, Ewing's Tumor Metastatic, Ewing's Sarcoma Metastatic
- Trial name
- VITA (NCT03495921)
- Testing
- Vigil, Irinotecan, Temozolomide
- Where
- 15 sites in United States
- Volunteers
- 32 people
- Sponsor
- Gradalis, Inc.
Rare Tumor, Refractory Tumor
Efficacy and Safety of Precision Therapy in Refractory Tumor
This study is intended to evaluate efficacy and safety of targeted precision therapy in patients with refractory tumor, including rare tumor without standard recommended treatment and common tumor after multiple line of therapy.
- Trial name
- NCT03239015
- Testing
- Gefitinib, Erlotinib, Afatinib
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Baodong Qin
CTC and Tumor Related Rare Cell
Identification and Evaluation of Circulating Tumor Cells and Tumor Related Rare Cells in Immunotherapy
The primary objective of this study is designed to evaluate the enumeration of circulating tumor cells and identify the potential biomarkers associated with clinical outcome.
- Trial name
- NCT03434912
- Where
- Taiwan
- Volunteers
- 80 people
- Sponsor
- MiCareo Taiwan Co., Ltd.
Rare Peritoneal Surface Malignancies, Pseudomyxoma Peritonei
French National Registry of Rare Peritoneal Surface Malignancies
Despite advances in the management of and changes in clinical practice, little is known about the epidemiology, patterns of care and outcomes of rare peritoneal surface malignancies patients in France.
- Conditions
- Rare Peritoneal Surface Malignancies, Pseudomyxoma Peritonei, Peritoneal Mesothelioma, Desmoplastic Small Round Cell Tumor
- Trial name
- RENAPE (NCT02834169)
- Testing
- Non interventional
- Where
- 33 sites in France
- Volunteers
- 2,171 people
- Sponsor
- Hospices Civils de Lyon
Anaplastic Astrocytoma, Anaplastic Oligodendroglioma
Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms
OBJECTIVES: I. Assess the clinical response of patients with refractory or recurrent brain neoplasms treated with carmustine, streptozocin, and mercaptopurine.
- Conditions
- Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Mixed Gliomas, Glioblastoma Multiforme
- Trial name
- NCT00004688
- Testing
- carmustine, mercaptopurine, streptozocin
- Volunteers
- 35 people
- Sponsor
- Emory University
Amyloidosis
Study of High-Dose Melphalan and Autologous Stem Cell Transplantation in Patients With Primary Light Chain Amyloidosis
OBJECTIVES: I. Determine the response, disease-free survival, and overall survival of patients with primary light chain amyloidosis treated with high-dose melphalan and autologous stem cell transplantation. II.
- Trial name
- NCT00017680
- Testing
- Melphalan, Autologous Stem Cell Transplantation
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Herbert Irving Comprehensive Cancer Center
Brain Neoplasms
Phase II Randomized Study of Stereotactic Radiosurgery Plus Fractionated Whole-Brain Radiotherapy Vs Fractionated Whole-Brain Radiotherapy Alone for Multiple Primary or Metastatic Brain Tumors
OBJECTIVES: I. Evaluate whether stereotactic radiosurgery provides local control at multiple sites in patients with primary or metastatic brain tumors, controlled systemic disease, and preserved neurologic function. II.
- Trial name
- NCT00004659
- Testing
- irradiation, radiosurgery
- Volunteers
- 40 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Fanconi's Anemia, Myelodysplastic Syndromes
Study of Allogeneic Bone Marrow Transplantation Following Cyclophosphamide and Radiotherapy in Patients With Myelodysplastic Syndrome and Acute Leukemia Related to Fanconi's Anemia
OBJECTIVES: I. Determine the effectiveness of moderate dose cyclophosphamide and radiotherapy in terms of improving survival and reducing the morbidity following allogeneic bone marrow transplantation in patients with…
- Conditions
- Fanconi's Anemia, Myelodysplastic Syndromes, Leukemia, Nonlymphocytic, Acute, Leukemia, Lymphocytic, Acute
- Trial name
- NCT00005892
- Testing
- cyclophosphamide, Allogeneic Bone Marrow Transplantation
- Where
- United States
- Sponsor
- Fairview University Medical Center